Ex Vivo drug sensitivity in patient-derived 3D cultures in acromegaly and its association with clinical predictors
Authors' conclusion
Spheroid-based Pd3D ex vivo viability assays revealed modest but significant cohort-level effects and sample-level concordance with clinical predictors, suggesting its potential utility as an exploratory model.
Study context
- Population
- Patients with acromegaly; Pd3D cultures of GH-secreting pituitary adenomas
- Participants
- 27 patients
- Comparison
- Octreotide, cabergoline or pasireotide vs vehicle control in Pd3D cultures
- Outcome
- Cell viability and responder rates (viability reduction vs vehicle, p < 0.05)
Methodological detailsex vivo, spheroid-based patient-derived 3D cultures
- Ex vivo
- Spheroid-based patient-derived 3D cultures
Main finding
As reported in the abstract
All agents modestly reduced median cell viability (p < 0.05)
84-86%
Responder rates
33-40%
Further findings
Concordance of responder status with established predictors
- Octreotide responders correlated with T2 hypointensity (p = 0.04)
- 88% vs 44%
- Cabergoline responders with positive bromocriptine tests (p = 0.03)
- 100% vs 45%
- Pasireotide responders with sparsely granulated patterns (p = 0.04)
- 64% vs 19%
SSTR2 expression after treatment (AI-based analysis in liquid-based cytology (LBC), 6 cases)
- Ex vivo responders showed relatively stable SSTR2 expression after treatment, whereas nonresponders exhibited marked depletion
Original publication
Ex Vivo drug sensitivity in patient-derived 3D cultures in acromegaly and its association with clinical predictors. Pituitary. Published 24 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →